Bare-Metal Stents
Boston Scientific’s bare-metal Rebel stent comes to the U.S.
Massachusetts medical device giant Boston Scientific (NYSE:BSX) today announced FDA approval for the latest in its line of coronary stents, the Rebel bare-metal stent.
Boston Scientific lands E.U. approval for Rebel bare-metal stent
Medtech titan Boston Scientific (NYSE:BSX) won European regulatory approval for its Rebel bare-metal stent, a drug-free version of its Promus Premier device.
Boston Scientific wraps up patient enrollment for Innova bare metal stent trial
Medical device giant Boston Scientific’s (NYSE:BSX) enrolled the last of 299 patients in its SuperNOVA trial, moving the company 1 step closer to completing the clinical evaluation of its Innova bare metal stent.
Gore lands CE Mark for its next-gen endoprosthesis
Stent Wars: DES best bare metal stents
Updated March 26, 2012 at 9:23 a.m. with new details on Promus/Xience private label deal and March 23, 2012 at 1:15 p.m. with comments from Medtronic.
SCAAR: Next-gen DES take the lead from BMS for lowest death risk
Next-generation drug-eluting stents proved safer than their predecessors and their bare-metal cousins for rates of restenosis, stent thrombosis and subsequent death, flipping the tables on previous findings.
New results from Swedish Coronary Angiography & Angioplasty Registry data taken between Nov. 2006 and Oct. 2010 show that DES have finally taken the lead for safety in the stent arena.
Boston Scientific launches bare-metal stent trial for next-generation Omega device
Boston Scientific Corp. (NYSE:BSX) launched a new global trial of its next-generation Omega bare-metal stent by enrolling its first patient in Latvia.
The trial will include up to 328 patients across 40 sites in the U.S. and Europe in efforts to determine the safety and effectiveness of the med-tech giant’s bare-metal stent in a single-arm prospective study of coronary artery disease patients.